Lomuto M, Calabrese P, Giuliani A
Dermatology Department, Casa Sollievo della Sofferenza Hospital-IRCCS, Viale Cappuccini, 71013 San Giovanni Rotondo, Italy.
J Eur Acad Dermatol Venereol. 2004 May;18(3):291-300. doi: 10.1111/j.1468-3083.2004.00895.x.
Prognoses for melanoma patients are currently based on statistically confirmed parameters, above all the Breslow thickness and number of lymph node and/or distant metastases. However, metastases can develop even with "thin" melanomas (< 0.7 mm), while survival has been recorded in patients with tumours classified as "thick" (> 4 mm). This review of the literature examines the most recent advances in prognostic markers for melanoma (serological, immunohistochemical, histological, genetic and surgical). These markers offer interesting possibilities in terms of diagnostic certainty, identification of early growth phases and estimation of the tumour's potential for progression and metastasis. It is reasonable to assume that their combined use can provide useful information for formulating prognoses that are not only statistically valid but also individualized.
黑色素瘤患者的预后目前基于经统计学证实的参数，首要的是 Breslow 厚度以及淋巴结和/或远处转移的数量。然而，即使是“薄”黑色素瘤（<0.7 毫米）也可能发生转移，而被归类为“厚”（>4 毫米）肿瘤的患者也有生存记录。本文献综述探讨了黑色素瘤预后标志物（血清学、免疫组织化学、组织学、遗传学和手术方面）的最新进展。这些标志物在诊断确定性、早期生长阶段识别以及肿瘤进展和转移潜能评估方面提供了有趣的可能性。合理的假设是，它们的联合使用可为制定不仅具有统计学有效性而且个性化的预后提供有用信息。
